Heidelberg and Inserm have scored exits after an acquisition that followed MYR's chronic hepatitis delta virus treatment receiving European regulatory approval.

MYR, a Germany-based chronic hepatitis therapy developer spun out of Heidelberg University and French state research institute Inserm, has agreed to an acquistion by pharmaceutical firm Gilead Sciences for nearly €1.2bn ($1.4bn) in cash. Gilead will pay the $1.4bn sum once the deal is completed, subject to customary conditions, and MYR could receive up to…

The rest of this content is only accessible to Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.